Letter to the Editor Regarding Erythropoietin-Stimulating Agents Resistance in Haemodialysis-Treated Patients: Time for a Treatment Shift?

Heart Lung Circ. 2023 Aug;32(8):e53-e54. doi: 10.1016/j.hlc.2023.05.007.

Authors

Roberto G Carbone¹, Simone Negrini², Francesco Puppo²

Affiliations

¹ Department of Internal Medicine, University of Genoa School of Medicine, Genoa, Italy. Electronic address: magister1@mail.com.
² Department of Internal Medicine, University of Genoa School of Medicine, Genoa, Italy.

PMID: 37673553
DOI: 10.1016/j.hlc.2023.05.007

No abstract available

Keywords: Anaemia; Cardiovascular disease; Chronic kidney disease; Erythropoietin-stimulating agents; Mortality.

Publication types

Letter
Comment

MeSH terms

Erythropoietin* / therapeutic use
Humans
Renal Dialysis*

Substances

Erythropoietin